The use of amantadine for treatment of hepatitis C.

摘要

Invention patent: b "use of amantadine for the treatment of hepatitis C" d . This invention aims to the treatment of patients with viral infection using the pharmaceutical agents.In the design of pharmaceutical agents of this invention are cyclic amines and, preferably, cu00edclias primary amines.In one of his conceptions, the pharmaceutical agent is amantadine and viral infection is hepatitis C.The design of the present invention supposes) the existence of: (I) a patient with symptoms of hepatitis C infection.(II) amantadine; and (b) the administration of a dose of amantadine for effective terpeuticamente referred to the patient under such conditions that the symptoms of this infection are reduzidThe. The prresente invention is not limited by the method of administration. In one of his conceptions, management is by the enteral route.In another design, the enteral administration is oral administration, and in another design, the enteral administration using polymeric microspheres.On the other hand, and still in another design, the administration is parenteral administration.In these designs, the parenteral administration can be topical administration or by means of adhesive patch.In another design, the parenteral administration is the subcutaneous administration; while in another design, the parenteral administration using aerosol.The present invention is not limited by the nature of the patient.In one design, the patient is a patient of naive (i.e., that had never been subjected to prior treatment for hepatitis C infection)While in other conceptions, the patient cannot be treated with interferon (e.g., cannot tolerate interferon or whose condition is not responsive to interferon).In another design, the patient is imunocompromissado. In one design, the patient has less than eighteen years of age.The present invention also is limited by the method of determination of dose response. In one design, the above symptoms include increased levels of aminotransferase in blood alamina (P.For example, serum) of the patient, while in other designs, these symptoms include ribonucleic acid of hepatitis C or the levels of antibodies against HCV in this patient.In another design, the above symptoms include the histology of liver biopsy, which is consistent with infection with hepatitis C.The present invention includes the use of various forms of amantadine. In one design, that amantadine is in the form of salt (e.g. hydrochloride, amantadine).In the same way, the present invention is not limited by the type of infection with hepatitis C.In one design, the infection by hepatitis C infection in chronic hepatitis C, while in another design, the hepatitis C infection is severe infection in hepatitis C.